Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 6, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback activity:
- Shares Purchased: 561,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,705.25 pence per share; lowest price paid was 1,678.50 pence per share.
- Treasury Holdings: Post-transaction, the Company holds 505,700,112 shares in Treasury (9.34% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 10.32% of total voting rights.
- Shares in Issue: 4,906,781,299 shares (excluding Treasury shares).
Material Changes
The filing does not provide comparative financial data against prior periods. The material change reported is the reduction of outstanding shares through the repurchase of 561,000 shares, which are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (505,700,112) against the latest annual report.
- Confirm the total issued share capital to validate the 9.34% Treasury ownership calculation.
- Check the status of the 561,000 shares purchased to ensure settlement is complete.
- Review the remaining authorization for share buybacks under the May 1, 2013 shareholder mandate.